Division of Mallinckrodt PLC
Latest From Stratatech Corp.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.
- Gene Therapy, Cell Therapy
- Large Molecule
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
B. Lynn Allen-Hoffmann, PhD, CEO & CSO
Cindy Ballweg, Dir., Fin. & Admin. & Treasurer
Allen Comer, PhD, Dir., R&D
David Hiller, Dir., Operations
- Contact Info
Phone: (608) 441-2750
505 S. Rosa Rd.
Madison, WI 53719
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.